Niklas Bergvall, Phd Email & Phone Number

Stockholm, Stockholm County, Sweden

Basel, Basel-Town, Switzerland

 Lead patient access and TA Policy for all pre-launch and in-market assets in multibillion neuroscience franchise– core member of Global Franchise LT and Global Patient Access LT Leading teams designing and executing strategies to achieve rapid and broad access at target price to neurology portfolio in US, EU5, Japan and China, with a key focus on pipeline assets and blockbuster launches Kesimpta –key launch asset for Novartis: o US - Achieved accelerated and favorable Kesimpta commercial payer coverage with expected net priceo EU - Broad and accelerated Kesimpta access achieved in all major markets at price targets (ex. France 6 months from approval & UK 2 months from approval) o JP - Accelerated access achieved Leading teams accountable for market access & pricing due diligence and commercial assessments of BD&L and M&A targets, ex. co-development and co-commercialization agreement in 2021 with UCB on early assets in Parkinson’s Disease, and acquisition of Cadent Therapeutics in 2020  Architect in organizational projects, creating more agile and impactful global organizations, and building experience in large scale organization transformations:o Neuroscience Patient Access & Therapeutic Area Policy team – changed from a reimbursement focused team to a fully Integrated Patient Access & Policy organization, with increased engagement with health-care system stakeholders (ex. EU Commission/Parliament, WHO/UN, Patient Advocacy and Policy groups)o Novartis Global Functions Transformation – Pharma Executive Committee sponsored project to transform Novartis global organization from an internal and function-focused organization into a customer-focused organization.

Basel Area, Switzerland

 Lead market access, health systems evidence, and market shaping for launch of Kesimpta  Architect of bold patient access & pricing strategy for Kesimpta - become first High Efficacy Treatment in MS to have unrestricted and accelerated access in US, EU5 and JP (see access outcomes listed above) and enable first line brand strategy  Successfully shaped label negotiations with FDA and EMA to ensure indication and USPI/SMPC supported execution of patient access and brand strategy Designed and executed a world-wide training program for commercial, medical and access associates to enable local execution of Kesimpta patient access strategy  Designed successful strategy to mitigate cross-indication access & pricing risks in Japan and Germany Selected for Wharton Marketing Executive Education Program

Cambridge, United Kingdom

 Lead market access, health systems evidence, early market shaping and healthcare systems partnerships for all pre-launch and in-market assets in multibillion respiratory portfolio Member of Global Franchise Leadership team and Global Market Access & Pricing Leadership Team, with 15 direct reports

 Lead market access and health systems evidence for launch of Ocrevus, and member of Ocrevus Lifecycle Team Partnered with Genentech to develop a disruptive pricing strategy that maximized the opportunity of launching under medical benefit and buy-n-bill model, and created significant commercial differentiation and enabled a successful lunch (blockbuster within 12 months from launch)  Secured access for both relapsing and primary progressive multiple sclerosis indications in priority markets and enabled foundation for one of Roche most successful assets (+4bn in sales) Selected for the 2018 Roche Explorations Leadership program

 Lead and execute global market access and health systems evidence strategies for full MS portfolio

Global HE&OR program lead for Gilenya and BAF312.

Basel Area, Switzerland

Global HE&OR program lead for Gilenya and BAF312.

National responsibility and accountability for all health economic activities, including price and reimbursement submissions, health economic modeling and HE&OR support to sales and marketing departments. Support function to health economic activities in Norway and Denmark.Major achievements: Reimbursement of Gilenya. Reimbursement of Tobi Podhaler

Responsible for national (price and reimbursement submissions. In addition I provide health economic and pricing support to key account manager, regional sales directors, and other key internal stakeholders. Development of local health economic and pricing tools (budget-impact models, simulation models, etc.). Major achievements:"Scandinavian 2009 Most Innovative" award for the development of interactive health economic sales tools.Reimbursement of Onbrez Breezhaler.

Promotion from Research Analyst.

Completed numerous health economic projects in the area of dementia, including statistical analysis plans for clinical trials, cost-of-illness studies, and cost-effectiveness models.

Advanced Marketing Capabilities Program

Doctor Of Philosophy - Phd, Epidemiology

Msc, Statistics

Exchange Student